Author(s):
V. S. Aher, B. A. Bhairav, R. B. Saudagar
Email(s):
vaishaliaher91@gmail.com
DOI:
10.5958/2231-5713.2016.00031.3 
Address:
V. S. Aher1, B. A. Bhairav2*, R. B. Saudagar1
1Department of Quality Assurance Techniques, R. G. Sapkal College of Pharmacy, Anjaneri,
Nashik, Maharashtra, India.
2*Department of Quality Assurance Techniques, R. G. Sapkal College of Pharmacy, Anjaneri,
Nashik, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 6,
Issue - 4,
Year - 2016
ABSTRACT:
Migraine is likely due to local cranial vasodilation and to release of sensory neuropeptide through nerve ending in the trigeminal system. Zolmitriptan is Serotonin 5-HT1D receptor agonist. It gives relief from pain, headache, and other symptoms of migraine including nausea, vomiting and sensitivity to light/ sound. In this study, mouth dissolving tablets were prepared by direct compression method. In the present work efforts have been made to formulation, evaluation and comparative study of Zolmitriptan mouth dissolving tablet by using direct compression method. Release profile of F-7 having 40% Croscarmellose sodium (disintegrant) and 13.3% Microcrystalline cellulose (suspending agent) in direct compression method was found to have maximum release of 99.24 %. The drug release from all batches was found to be concentration dependent. Hence, the formulation of F-7 fulfills the objective of the present study.
Cite this article:
V. S. Aher, B. A. Bhairav, R. B. Saudagar. Formulation, Evaluation and comparative study of Zolmitriptan Mouth Dissolving Tablet. Asian J. Pharm. Tech. 2016; 6(4): 207-216. doi: 10.5958/2231-5713.2016.00031.3
Cite(Electronic):
V. S. Aher, B. A. Bhairav, R. B. Saudagar. Formulation, Evaluation and comparative study of Zolmitriptan Mouth Dissolving Tablet. Asian J. Pharm. Tech. 2016; 6(4): 207-216. doi: 10.5958/2231-5713.2016.00031.3 Available on: https://ajptonline.com/AbstractView.aspx?PID=2016-6-4-3